40 years

Bringing science to patients since 1979

AstraZeneca

Growth through innovation

40 years and beyond

AstraZeneca Pharma India Limited

Annual Report 2018-19

About AstraZeneca Pharma India Limited (AstraZeneca)

AstraZeneca was established in 1979 and is headquartered at Bengaluru, Karnataka. It is a listed operating Company and conducts manufacturing, sales and marketing activities in India.

READ INSIDE

Corporate Overview

AstraZeneca at a Glance	02
Key Milestones	04
Focus on Sustainability	06

Statutory Reports

Corporate Information	09
Notice	10
Board's Report	19
Management Discussion & Analysis Report	37
Report on Corporate Governance	41
Business Responsibility Report	55

Financial Statements

Independent Auditor's Report	62
Balance Sheet	68
Statement of Profit and Loss	69
Statement of Changes in Equity	70
Statement of Cash Flows	71
Notes to the Financial Statements	72
Ten Year Summary	108

Among

Top 100

Best Companies for Women, 2018 by Avatar & Working Mothers

GPTW

AstraZeneca was certified as 'Great Place to Work' in 2018

1,400+

Employees working across the country

Celebrating 40 years of *bringing science to patients in India.*

AstraZeneca is celebrating its four-decade long commitment to India of delivering life-changing medicines to patients through innovative science. The Company today has over 1,400 employees, a unique portfolio of innovative healthcare products and a state-of-the-art manufacturing facility at Bengaluru, India, designed to meet the most stringent international standards, conforming to WHO cGMP (current Good Manufacturing Practices) norms.

AstraZeneca through its flagship programmes – Young Health Programme, Early Action in Diabetes, Healthy Lung and Ganga Godavari Early Cancer Screening Programme – is at the forefront of addressing the unmet needs in Non-Communicable Diseases (NCDs) such as diabetes, heart diseases, asthma & COPD, and cancer. With its focus on growth through innovation, the Company is on track to become a leader in its chosen therapeutic areas by delivering growth, accelerating innovative science and being a great place to work.



Pushing the Boundaries of Science

Our science-led strategy and our open and entrepreneurial culture are underpinning a resurgence in innovation that is fuelling sustainable product sales growth and delivering medicines that patients and society value and can access.

Pascal Soriot
Chief Executive Officer, AstraZeneca PLC
(Source: AstraZeneca PLC - Annual Report 2018)



Our Values Drive Us

Our values and behavioural statements have been updated to reflect that we innovate best when building networks across the enterprise, including differentiated thinking to challenge the status quo, while also generating ideas and solving problems together.

Our Strategic Priorities

As we look to the future, our strategic priorities have evolved to reflect what we need to deliver in the next phase of our journey.

Delivering growth and therapy area leadership

Accelerate innovative science

Be a great place to work

Our Core Therapy Areas

Cardiovascular, Renal and Metabolic diseases

We maintain an integrated patient approach to reduce cardiovascular morbidity and mortality.

Oncology

We are redefining the treatment paradigm to eliminate cancer as a cause of death.

Respiratory, Inflammation and Autoimmunity

We have immense potential to deliver scientific breakthroughs and transform the lives of people through our 40-year experience in respiratory science.

Key Brands

Forxiga® (Dapagliflozin)

Brilinta® (Ticagrelor)

Xigduo® XR (Dapagliflozin + Metformin HCl (Extended Release)

Crestor® (Rosuvastatin)

Tagrisso™ (Osimertinib)

Lynparza® (Olaparib)

Zoladex® (Goserelin Acetate Depot Injection)

Symbicort® (Budesonide/Formoterol Inhalation Powder)

Our Four-decade Journey

At AstraZeneca, we believe the best way we can help patients is to focus on breakthrough science in order to uncover disease mechanisms and develop novel, targeted therapies that interact with them. At the heart of our purpose as a Company is to push the boundaries of science to deliver life changing medicines.

1979

Astra IDL formation

1982

Astra factory foundation

1992

Launch of Cerviprime, Plendil, Ramace, Rhinocort and Imdur

2001

Merger of Astra & Zeneca in 1999 globally, formed 'AstraZeneca' name in India in 2001

2015

Launch of Forxiga

forxiga

2017

Launch of Tagrisso

TAGRISSO™ osimertinib

2018

Launch of Xigduo XR

kombiglyze XR

Launch of first Metabolic Centre of Excellence in India

2019

Launch of Lynparza

Lynparza olaparib

2002

Zoladex®

Launch of Meronem and Zoladex

2003

Seloken XL

Launch of Seloken XL

2007

FASLODEX® fulvestrant 250 mg injection

Launch of Faslodex

2008

THAT CONFIDENT FEELING Symbicort

Launch of Symbicort

2009

Launch of Crestor

CRESTOR® Rosuvastatin Tablets IP 5/10/20/40 mg
AT THE CREST OF CV PROTECTION

2010

Launch of Onglyza and introduction of Young Health Programme, India

onglyza

AstraZeneca Young Health Programme
A global community investment initiative

2012

Launch of Brilinta and Kombiglyze

BRILINTA

kombiglyze XR

2014

New Tablet Production Facility

Making Science Accessible

As a science-led biopharmaceutical company, we want to be valued and trusted by our stakeholders as a source of great medicines over the long term. We are committed to operating in a way that recognises the interconnection between business growth, the needs of society and the limitations of our planet.

What does making science accessible really mean to us?

Access to healthcare

- Connecting our business growth to positive impact for the society.
- Setting goals and building on systems that support people around the world towards a healthier future.

Enviromental protection

- The health of the environment has a huge impact on human wellbeing.
- From climate change to consumption, we are all responsible for reducing our dependence on natural resources.

Ethics and transparency

- Putting our Values at the forefront of our decision-making.
- From sales and marketing to clinical trial transparency and bioethics, it's one way we meet stakeholder expectations.

Access to Healthcare

We are using our science to improve health. Non-communicable diseases (NCDs) account for seven out of ten deaths globally, making them the leading cause of death worldwide. Our access to healthcare strategy in India focusses on three areas - making our medicines available and affordable, supporting sustainable health systems and infrastructure and promoting disease awareness and prevention.

AstraZeneca has launched a number of flagship programmes to increase access to healthcare in India.

Ganga Godavari Early Cancer Screening Programme

Launched in February 2019 on World Cancer Day, AstraZeneca is proud to partner with the Indian Cancer Society and the Charities Aid Foundation India for the Early Cancer Screening and Awareness Programme for women, especially in areas where access to healthcare facilities are constrained. The key components of this programme include specialised cancer screening camps for females in defined population for oral, breast and cervical cancer, create awareness through health education activities in the community and robust follow up process to ensure referral for treatment at cancer hospitals.

2,000+

Beneficiaries in Phase 1

10+

States identified; focus on high priority districts

Focus

On women from underprivileged sections

The Young Health Programme (YHP)
The YHP India is funded and supported by AstraZeneca Global and was launched in India in 2010. AstraZeneca's contribution to YHP India include employee engagement and disease awareness initiatives among communities. YHP focuses on prevention of NCD's during adolescence by education on risk behaviours such as tobacco use, alcohol abuse and unhealthy eating through on-ground programmes, research and evidence generation and advocacy - empowering young people to make informed choices that protect their health, now and in the future.

350,000

Young people aged 10-24 directly benefitted

3,000+

Close to 3,000 young people have been trained to be educators in their local communities

15

Health Information Centers are providing preventive and promotive health and counselling services

It was a great experience. I was so delighted to see the confidence and ability of these young people who had learnt and are able to teach other people on the importance of healthy lifestyle to combat Non-Communicable Diseases. It is hugely encouraging to see the impact and the reach of this programme.

Narayan K Seshadri
Chairman of the Board, AstraZeneca India, during the Board members' visit to YHP Communities at Delhi

Early Action in Diabetes
AstraZeneca partnered with the Department of Health and Family Welfare, Government of Kerala in 2018 to launch a 360° Metabolic Centre of Excellence that aims to provide comprehensive management of diabetes and associated metabolic conditions.

Healthy Lung India
The Healthy Lung Programme India aims to raise the profile of Asthma & COPD and transform the standard of care of these conditions. This includes capacity building of healthcare professionals, medical infrastructure and policy advocacy to better serve patients. In partnership with Employees State Insurance Corporation (ESIC), Government of India, AstraZeneca launched the first Healthy Lung Centres in ESIC Jamshedpur, Patna and Ranchi with a shared objective of improving the quality of care provided to the beneficiaries of ESIC.

iDREAM Hub

The iDREAM hub in India was established as part of the recent expansion of AstraZeneca's strategic collaborations to address the rising burden of NCDs in the country, building on the foundation of the bilateral innovation partnership between India and Sweden, signed in 2018. It will complement AstraZeneca's strategic partnership with the National Association of Software and Services Companies (NASSCOM), enabling the Company to run an accelerator for health start-ups in collaboration with NASSCOM's Centre of Excellence for Internet of Things, the largest platform for deep technology innovation in India. This iDREAM hub intends to support the thriving start-up culture in India, enabling the Company to mentor exciting new research and create affordable and accessible healthcare solutions.

As a science-led organisation, AstraZeneca is committed to strengthen innovation in healthcare in India. We are pleased to collaborate with the government, start-up eco-system and industry partners to achieve the shared vision of making meaningful interventions in improving the lives of patients impacted by Non-Communicable diseases in India.

Leif Johansson

Chairman of the Board, AstraZeneca PLC present at the Unnati Healthcare Day hosted by AstraZeneca, Business Sweden and Atal Innovation Mission- Niti Aayog in February 2019.

National Community Service Week to Mark 40 Years

In a one of a kind initiative to mark AstraZeneca's 40th business anniversary, AstraZeneca, in partnership with Plan International (India chapter), undertook a national scale programme to sensitise school children on NCD related risk behaviour such as tobacco use, alcohol abuse, lack of physical exercise and unhealthy eating. Under this programme, AstraZeneca partnered with over 25 government/community run schools across 12 cities in India. Engaging and fun ways such as street plays, drawing and quiz competitions, debates and counselling were used to convey the message to the children. More than 700 employees of the Company came forward to contribute their time for this programme.